An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Pfizer
Daiichi Sankyo
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
Bristol-Myers Squibb
Bristol-Myers Squibb
Hoffmann-La Roche
Daiichi Sankyo
Bayer
Bristol-Myers Squibb
Hoffmann-La Roche
Hoffmann-La Roche
Regeneron Pharmaceuticals
Novartis
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Pfizer
Novartis
Pfizer
AstraZeneca
Merck Sharp & Dohme LLC
Novartis
Takeda
Gilead Sciences
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim